Based on in vitro and in vivo evaluations, it is conceivable to design a formulation and continue preclinically and clinically assessing I-C19 and 131I-C19 as potential molecules for the treatment of K-Ras4B-dependent or K-Ras4B-independent colon cancers. This evidence concerns the gene KRAS and malignant colon neoplasm.